Neurizon Therapeutics 관리

관리 기준 확인 1/4

Neurizon Therapeutics CEO는 Michael Thurn, May2024 에 임명되었습니다 의 임기는 1년 미만입니다. 총 연간 보상은 A$ 415.11K, 69.4% 로 구성됩니다. 69.4% 급여 및 30.6% 보너스(회사 주식 및 옵션 포함). 는 A$ 536.00K 가치에 해당하는 회사 주식의 0.58% 직접 소유합니다. 536.00K. 경영진과 이사회의 평균 재임 기간은 각각 0.5 년과 0.5 년입니다.

주요 정보

Michael Thurn

최고 경영자

AU$415.1k

총 보상

CEO 급여 비율	69.4%
CEO 임기	less than a year
CEO 소유권	0.6%
경영진 평균 재임 기간	less than a year
이사회 평균 재임 기간	less than a year

최근 관리 업데이트

Recent updates

CEO 보상 분석

Michael Thurn 의 보수는 Neurizon Therapeutics 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	AU$415k	AU$288k	-AU$9m

보상 대 시장: Michael 의 총 보상 ($USD 269.76K )은 Australian 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 297.81K ).

보상과 수익: Michael 의 보상을 회사 성과와 비교하기에는 데이터가 부족합니다.

CEO

Michael Thurn

less than a year

테뉴어

AU$415,107

보상

Dr. Michael Thurn, Ph D., serves as Managing Director, CEO and Director of PharmAust Limit since May 31, 2024. He was Chief Executive Officer of Neurizon Therapeutics Limited (formerly known as PharmAust L...

리더십 팀

이름	위치	테뉴어	보상	소유권
Michael Thurn	MD, CEO & Director	less than a year	AU$415.11k	0.58% A$ 536.0k
John Clark	Chief Operating Officer	less than a year	AU$153.58k	0.13% A$ 118.7k
Nicky Wallis	Chief Scientific Officer	less than a year	AU$26.16k	데이터 없음
Fiona Milner	General Manager of Epichem Pty Ltd	2.4yrs	AU$26.69k	데이터 없음
Gary Pitt	Head of Chemistry	no data	데이터 없음	데이터 없음
James Rixson	Head of Production	no data	데이터 없음	데이터 없음
Herbert Brinkman	Head of Manufacturing	less than a year	데이터 없음	데이터 없음
Stefan Ross	Company Secretary	less than a year	데이터 없음	데이터 없음

0.5yrs

평균 재임 기간

경험이 풍부한 관리: NUZ 의 관리팀은 경험 (평균 재직 기간 0.5 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Michael Thurn	MD, CEO & Director	less than a year	AU$415.11k	0.58% A$ 536.0k
Kathryn MacFarlane	Director	less than a year	AU$3.13k	0.054% A$ 50.0k
Christian Schirvel	Veterinary Clinical Advisory Board Member	7.1yrs	데이터 없음	데이터 없음
Angela Frimberger	Veterinary Clinical Advisory Board Chair	7.1yrs	데이터 없음	데이터 없음
Barbara Kitchell	Veterinary Advisory Board Member	6.9yrs	데이터 없음	데이터 없음
Marcus Hughes	Director	less than a year	AU$10.80k	2.97% A$ 2.7m
Sergio Duchini	Non-Executive Chairman	less than a year	AU$9.38k	0.27% A$ 250.0k

0.5yrs

평균 재임 기간

경험이 풍부한 이사회: NUZ 의 이사회는 경험(평균 재직 기간 0.5 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

Neurizon Therapeutics 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

PharmAust Limited, Annual General Meeting, Sep 30, 2024

PharmAust Limited, Annual General Meeting, Nov 20, 2023

PharmAust Limited Announces Executive Changes

PharmAust Limited Appoints Roger Aston as Non-Executive Chairman, Effective 1 September 2023

No independent directors

PharmAust Limited, Annual General Meeting, Nov 10, 2022

Recent updates

Neurizon's NUZ-001 Reduces Aggregation of Key ALS Disease Target TDP-43 in Preclinical Study

PharmAust Limited, Annual General Meeting, Sep 30, 2024

PharmAust Limited has filed a Follow-on Equity Offering.

PharmAust Limited has completed a Follow-on Equity Offering in the amount of AUD 3.459 million.

PharmAust Limited has announced a Derivatives Offering in the amount of AUD 39.612456 million.

PharmAust Limited, Annual General Meeting, Nov 20, 2023

Full year 2023 earnings released: AU$0.019 loss per share (vs AU$0.005 loss in FY 2022)

New minor risk - Financial data availability

PharmAust Limited Announces Executive Changes

PharmAust Limited Appoints Roger Aston as Non-Executive Chairman, Effective 1 September 2023

First half 2023 earnings released: EPS: AU$0 (vs AU$0.004 loss in 1H 2022)

PharmAust Limited Progresses to Elevated Doses in MND Patients

PharmAust Limited Completes First Cohort of Six Patients in Its Phase 1/2 Clinical Trial of Lead Drug Candidate Monepantel in Motor Neurone Disease/Amyotrophic Lateral Sclerosis

PharmAust Limited Announces MND Trial Completes Enrolment of First Patient Cohort

No independent directors

PharmAust Limited, Annual General Meeting, Nov 10, 2022

PharmAust Limited Recruits First Pet Dog with B Cell Lymphoma in US Canine Phase 2 Trial Assessing the Efficacy of Monepantel Treatment

Full year 2022 earnings released: AU$0.005 loss per share (vs AU$0.004 loss in FY 2021)

Pharmaust Updates on Canine Cancer Trials

PharmAust Limited Announces Resignation of Richard Mollard as Chief Scientific Officer

Pharmaust Limited Announces Arrival of Mpl Tablets in Melbourne for Motor Neuron Disease Clinical Trial

PharmAust Limited Expands Lymphoma Canine Trial to the USA

No independent directors

PharmAust Limited Announces Preliminary MPL Anti-Viral Leukaemia Preclinical WEHI Results

Pharmaust Limited Engages Ergomed Clinical Research Ltd to Commence Clinical Trials Testing the Anti-Viral Effects of Monepantel

First half 2022 earnings: Revenues and EPS in line with analyst expectations

PharmAust Limited Provides Update on Manufacture of MPL & Tablets for Clinical Trials

Full year 2021 earnings released: AU$0.004 loss per share (vs AU$0.005 loss in FY 2020)

Pharmaust Limited Achieves Phase IIB Dog Trial's Interim Clinical Endpoints

PharmAust Receives Ethics Approval for Phase I Trial of Monepantel in Motor Neurone Disease

PharmAust Limited Announces Phase IIb Canine Trial Identifies Therapeutic Window for MPL

PharmAust Ltd Provides an Update on Phase IIb Trial Testing the Effects of Monepantel Upon Pet Owners' Dogs with Treatment Naïve B Cell Lymphoma

PharmAust Limited Announces Monepantel COVID-19 Testing in the Netherlands

PharmAust and Leiden University Medical Centre Provide Update on Monepantel COVID-19 Testing

PharmAust and Olivia Newton-John Cancer Research Institute to Continue MPL Pre-clinical Investigations

PharmAust Ltd to Commence Phase IIb Dog Cancer Trial

PharmAust Limited Provides an Update on Analysis at the Olivia Newton-John Cancer Research Institute Investigating the Mechanism of Action of Monepantel Upon Cancer Cells

Pharmaust Ltd, Entered into A Service Agreement with Leiden University Medical Center (Lumc) in Netherlands for Lumc to Test

Full year earnings released - AU$0.0046 loss per share

Full year earnings released - AU$0.0046 loss per share

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

이사회 구성원

평균 재임 기간